Special Issue "Inflammation and Cancer"
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (16 April 2018)
Dr. Shairaz Baksh
Inflammation is a complex defense mechanism against biological and chemical insults. Although beneficial, persistent inflammation can cause cellular damage resulting in many diseases including obesity, diabetes, inflammatory bowel disease (IBD), cancer, schizophrenia and recently, Parkinson’s Disease. It is estimated that about 15–20% of all cancer cases are preceded by chronic inflammation, including lung, colon and pancreatic cancers to mention a few. Hanahan and Weinberg in 2011 categorized “tumor inflammation” and “avoiding immune detection” as “Hallmarks of Cancer”. Thus, there is a great need to understand how inflammation is regulated - both modulation of the threshold of activation and factors effectively deactivating it, in a timely manner, when not needed.
Some of the molecular drivers of inflammation have been repeatedly demonstrated to influence cell death, growth and metabolic pathways of a pre-cancer or cancer cell. The challenge is to understand how these molecular drivers differ from their function in normal cells and in homeostatic regulation. If key molecular drivers of inflammation to cancer can be identified, novel therapies can be obtained to selectively target their abnormal function in “inflammatory phase” prior to pre-cancer or cancer cells. This Special Issue on “Inflammation and Cancer” will provide an open-source sharing of significant articles describing the role for new and emerging players in regulating inflammation and how these players may impinge of the cell death, metabolic and growth characteristics of a pre-cancer or cancer cell (to mention a few).
Topics of this Special Issue include, but are not limited to:
- The Use of Organoids to explore inflammation and cancer
- Targeting tumor-promoting inflammation through lysophosphatidate signaling in cancer therapy
- Oncometabolism and Inflammation
- Inflammation as a driver of development of hematologic malignancies
- Roles for Siglecs in Modulating Inflammation in Cancer
- The relationship between malnutrition, inflammation and immune suppression in cancer
- The role for non-receptor protein tyrosine kinases, HPK1, in immunocheckpoint control
- RIPK2: New Elements in Modulating Inflammatory Breast Cancer Pathogenesis
- The complex interplay between chronic inflammation, the microbiome and cancer: understanding disease progression and what we can do to prevent it
If you have a topic that you would like to contribute to this Special Issue, please email Dr. Shairaz Baksh at [email protected] and we will do our best to incorporate it into our Special Issue. Thanks for your time.
Dr. Shairaz Baksh
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Tumor suppressor protein
- Metabolic syndrome
- 3D orgaonids/spheroids
- Cell death